Literature DB >> 1338224

Amine uptake inhibition by diosmin and diosmetin in human neuronal and neuroendocrine cell lines.

E Sher1, A Codignola, E Biancardi, D Cova, F Clementi.   

Abstract

Human neuroblastoma cells of sympathetic origin have been used for studying the effects of diosmin and its metabolite diosmetin (vasotonic agent) on amine reuptake systems. Neuroblastoma cells take up 3H-dopamine in a specific and time-dependent manner. 3H-dopamine uptake was dose-dependently inhibited by the known antagonist desipramine. Diosmin did not affect 3H-dopamine uptake at concentrations as high as 1 mM. On the other hand the aglycone metabolite of diosmin, diosmetin, inhibited 3H-dopamine uptake in a dose-dependent manner (IC50 = 4 microM). Diosmetin inhibited 3H-dopamine uptake in control and differentiated neuroblastoma cells, as well as in small-cell lung carcinoma cells. Furthermore diosmetin also inhibited 3H-serotonin uptake in both cell types. These results demonstrate that some flavonoids act as antagonists of plasma membrane amine transporters at the molecular level and suggest that inhibition of amine reuptake at the level of peripheral sympathetic nerve terminals could be responsible for the increased vascular tone observed in vivo after treatment with these drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1338224     DOI: 10.1016/1043-6618(92)90238-7

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  2 in total

1.  Diosmetin attenuates oxidative stress-induced damage to lens epithelial cells via the mitogen-activated protein kinase (MAPK) pathway.

Authors:  Guanghai Guo; Jin Dong
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

2.  Uncommon serum creatine phosphokinase and lactic dehydrogenase increase during diosmin therapy: two case reports.

Authors:  Giulia Milano; Silvia Leone; Carmen Fucile; Maria Laura Zuccoli; Andrea Stimamiglio; Antonietta Martelli; Francesca Mattioli
Journal:  J Med Case Rep       Date:  2014-06-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.